PCVX vs. UTHR: A Head-to-Head Stock Comparison

Updated on October 4, 2025

Here’s a clear look at PCVX and UTHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	PCVX	UTHR
Company Name	Vaxcyte, Inc.	United Therapeutics Corporation
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	5.54 billion USD	19.82 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	June 12, 2020	June 17, 1999
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of PCVX and UTHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

PCVX vs. UTHR: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	PCVX	UTHR
5-Day Price Return	23.12%	-4.45%
13-Week Price Return	28.30%	45.89%
26-Week Price Return	12.98%	34.87%
52-Week Price Return	-62.66%	16.92%
Month-to-Date Return	18.43%	37.55%
Year-to-Date Return	-47.89%	18.81%
10-Day Avg. Volume	2.04M	1.03M
3-Month Avg. Volume	1.58M	0.73M
3-Month Volatility	49.34%	72.29%
Beta	1.27	0.78

Profitability

Return on Equity (TTM)

PCVX

-16.85%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

PCVX has a negative Return on Equity of -16.85%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

UTHR

18.73%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, UTHR’s Return on Equity of 18.73% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

PCVX vs. UTHR: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

PCVX

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

Net Profit Margin data for PCVX is currently unavailable.

UTHR

40.36%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

A Net Profit Margin of 40.36% places UTHR in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

PCVX vs. UTHR: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

PCVX

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

Operating Profit Margin data for PCVX is currently unavailable.

UTHR

47.05%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 47.05% places UTHR in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

PCVX vs. UTHR: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	PCVX	UTHR
Return on Equity (TTM)	-16.85%	18.73%
Return on Assets (TTM)	-15.92%	16.48%
Net Profit Margin (TTM)	--	40.36%
Operating Profit Margin (TTM)	--	47.05%
Gross Profit Margin (TTM)	--	88.98%

Financial Strength

Current Ratio (MRQ)

PCVX

11.11

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

PCVX’s Current Ratio of 11.11 is in the upper quartile for the Biotechnology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

UTHR

7.26

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

UTHR’s Current Ratio of 7.26 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

PCVX vs. UTHR: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

PCVX

0.00

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

PCVX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

UTHR

0.00

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

UTHR’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

PCVX vs. UTHR: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

PCVX

-41.28

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

PCVX has a negative Interest Coverage Ratio of -41.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

UTHR

42.15

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

UTHR’s Interest Coverage Ratio of 42.15 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

PCVX vs. UTHR: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	PCVX	UTHR
Current Ratio (MRQ)	11.11	7.26
Quick Ratio (MRQ)	10.75	6.94
Debt-to-Equity Ratio (MRQ)	0.00	0.00
Interest Coverage Ratio (TTM)	-41.28	42.15

Growth

Revenue Growth

PCVX vs. UTHR: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

PCVX vs. UTHR: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

PCVX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

UTHR

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PCVX vs. UTHR: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

PCVX

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PCVX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

UTHR

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

PCVX vs. UTHR: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	PCVX	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

PCVX

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for PCVX is currently unavailable.

UTHR

15.37

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

In the lower quartile for the Biotechnology industry, UTHR’s P/E Ratio of 15.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

PCVX vs. UTHR: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

PCVX

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

P/S Ratio data for PCVX is currently unavailable.

UTHR

6.20

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

UTHR’s P/S Ratio of 6.20 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PCVX vs. UTHR: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

PCVX

1.37

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

PCVX’s P/B Ratio of 1.37 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

UTHR

1.81

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

UTHR’s P/B Ratio of 1.81 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

PCVX vs. UTHR: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	PCVX	UTHR
Price-to-Earnings Ratio (TTM)	--	15.37
Price-to-Sales Ratio (TTM)	--	6.20
Price-to-Book Ratio (MRQ)	1.37	1.81
Price-to-Free Cash Flow Ratio (TTM)	--	17.83